Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05717920 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05717920: Completed Phase 2 study, sponsored by Aldeyra Therapeutics.
NCT05717920 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05717920, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
Primary Outcome
Incidence and severity of AEs
Interventions
- DRUG ADX-629 (Open-label)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2023-11-21 |
| Phase | Phase 2 |
What the finished NCT05717920 record still lists
NCT05717920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which ADX-629 (Open-label) is the first listed.
NCT05717920 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05717920 about?
NCT05717920 is a clinical study titled "A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)". A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.
What is the current status of trial NCT05717920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2023-02-15. Estimated completion is 2023-11-21.
What interventions are being tested in trial NCT05717920?
The interventions under investigation include: ADX-629 (Open-label) (DRUG).
Who is sponsoring clinical trial NCT05717920?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05717920's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI